Qrons Inc. is a cognitive wellness company focused on enhancing mental performance through innovative nutraceuticals and functional beverages, following its merger with First Person Ltd.

# Qrons Inc. Overview

## Company Background
- **Incorporation:** Qrons Inc. was incorporated under the laws of Wyoming on August 22, 2016, originally named BioLabMart Inc. It changed its name to Qrons Inc. on August 8, 2017.
- **Location:** Principal executive office located at 611 N. Brand Boulevard, Suite 1300, Glendale, California 91203.
- **Industry Focus:** Initially focused on biotechnology products for neuronal and infectious diseases before pivoting to cognitive wellness through the acquisition of its subsidiary, First Person Ltd., in January 2025.

## Business Operations
- **Acquisition of First Person Ltd.:** The acquisition emphasizes enhancing mental performance and social well-being through innovative, science-backed consumer products. The merger allowed Qrons to enter the rapidly growing market of cognitive wellness and functional beverages.

### Products
- **Current Offerings:**
  - **Cognitive Nutraceuticals:** Four initial products aimed at enhancing cognitive functions:
    1. **Sunbeam:** Enhances dopamine levels, promoting motivation and focus.
    2. **Golden Hour:** Targets oxytocin to promote feelings of connection and joy.
    3. **Moonlight:** Aimed at improving sleep cycles through gamma-aminobutyric acid (GABA).
    4. **Crystallized Lion’s Mane:** A drink enhancer that claims to enhance energy, mood, and focus.
    
- **Ready-To-Drink Alcohol-Free Beverages:** The company is developing a line of social tonics that leverage proprietary ingredients and extraction methods.

## Market and Customers
- **Target Audience:** The company targets consumers interested in cognitive health, nutrition, and mindful drinking, capitalizing on growing trends in alcohol alternatives and nootropic supplements.
- **Customer Base:** Specific numbers of customers or consumer adoption rates are not provided, but the products are sold directly to consumers via the company's website, **www.getfirstperson.com**, with options for one-time purchases and subscriptions.

## Financial Information
- **Revenue:**
  - As of December 31, 2024, Qrons did not generate any revenue. The merger with First Person is expected to enhance revenue potential by tapping into established customer bases and new product lines.
  
- **Expenses:**
  - For the fiscal year ended December 31, 2024, operating expenses amounted to **$344,476**, down from **$643,677** in 2023, demonstrating cost optimization.
  
- **Net Loss:**
  - The net loss for the year ended December 31, 2024, was **$56,097**, significantly lower than the **$789,347** loss reported for 2023.

- **Employees:** As of the date of the report, Qrons had one full-time employee in the U.S. and no full-time employees in Canada, mainly relying on outsourced talent and strategic partnerships.

## Strategic Vision
- **Future Plans:** The company aims to leverage its proprietary extraction technology to expand its functional wellness product offerings, aiming for growth in both the nutraceutical and non-alcoholic beverage markets.

## Conclusion
Qrons Inc. is strategically positioned in the emerging field of cognitive wellness with a clear focus on leveraging innovative products to meet consumer demands for mental health and nutrition solutions. Although currently at a net loss with no revenue, the recent merger with First Person and planned product expansions suggest significant growth potential in the near future.

Qrons Inc. is a biotechnology company focused on developing treatments for neuronal and infectious diseases, particularly antibiotic-resistant bacteria and Sepsis.

# Qrons Inc. Overview

## Company Profile
**Name:** Qrons Inc.  
**Incorporated:** August 22, 2016 (originally as BioLabMart Inc.)  
**Headquarters:** Long Island City, New York  
**Trading Symbol:** QRON (OTCQB)  
**Fiscal Year End:** December 31  

### Business Focus
Qrons Inc. is an innovative biotechnology company dedicated to developing products, treatments, and technologies aimed at combating **neuronal** and **infectious diseases**. It has a particular focus on addressing issues related to **antibiotic-resistant bacteria**, which poses a growing global health crisis.

### Product Candidates
1. **QS100™**
   - **Description:** A 3D printable, implantable mesenchymal stem cells (MSCs) synthetic hydrogel designed to treat penetrating brain injuries (e.g., from gunshot wounds, accidents).
   
2. **QS200™**
   - **Description:** An injectable MSCs-synthetic hydrogel intended for treating concussions and other diffused axonal injuries.

### Research Collaborations
The company collaborates with universities and scientists, particularly those in Israel, renowned for their advancements in biotechnology. Key collaborations include:
- Partnership with **Bar Ilan University** to improve solubility and treatment efficacy for diffused axonal injuries.
- Licensing agreements for utilizing certain **Tellurium-based compounds** to combat antibiotic resistance and Sepsis.

### Current Focus
In 2023, Qrons redirected its resources to concentrate on the **Sepsis** treatment, believing this focus could lead to faster commercialization.

### Financial Overview
- **Employees:** As of December 31, 2023, the company has two primary executive officers, with additional roles outsourced to contractors and advisors.
- **Customers:** Qrons does not currently have revenue-generating products and has not reported any sales to date.
- **Revenue:** The company has yet to generate revenue since its inception, with a total net loss of **$789,347** for the year ending December 31, 2023.
- **Total Operating Expenses (2023):** **$643,677**, largely due to research and development costs ($462,459).

### Current Market Environment
Qrons operates within a competitive biotechnology landscape, aiming to develop treatments for conditions that currently lack effective solutions. Although it does not directly compete with marketed products yet, it faces competition from larger pharmaceutical companies and ongoing research initiatives.

### Funding and Financial Needs
- The company is in a precarious financial position, reliant on loans and advances from its officers and shareholders to sustain operations.
- **Liquidity Concerns:** As of December 31, 2023, the company held just **$420** in cash, raising substantial doubt about its ability to continue as a going concern without additional funding or strategic partnerships.

## Conclusion
Qrons Inc. is primarily focused on the development of innovative treatments for severe neuronal injuries and infections, including antibiotic resistance and Sepsis. As of now, the company has not generated any revenue and relies heavily on the financial support of its founders and potential future partnerships to continue its operations and research efforts.

Qrons Inc.

10-K / April 16, 2025

10-K / April 15, 2024

10-K / April 16, 2025

Qrons Inc. Overview

Company Background

Business Operations

Products

Market and Customers

Financial Information

Strategic Vision

Conclusion